Examining the efficacy of treatment outcomes for patients with pulmonary tuberculosis in Western China: A retrospective study in a region of high incidence
- PMID: 40217246
- PMCID: PMC11987298
- DOI: 10.1186/s12889-025-22543-4
Examining the efficacy of treatment outcomes for patients with pulmonary tuberculosis in Western China: A retrospective study in a region of high incidence
Abstract
Background: Guizhou, situated in western China, exhibits a high incidence of pulmonary tuberculosis (PTB) alongside comparatively challenging medical and economic conditions. Our objective was to investigate the determinants influencing successful PTB treatment and their scope, aiming to provide a scientific foundation for targeted interventions and enhancing treatment efficacy.
Methods: Data encompassing all PTB cases registered in Guizhou's China Disease Prevention and Control Information System from 2017 to 2022 were analyzed. Using the successful treatment rate as the dependent variable, initial univariate analysis of independent variables was conducted, followed by multilevel binary logistic regression analysis to assess variables demonstrating statistically significant disparities.
Results: A total of 139,414 patients (average age: 44 years) were included, with 64.41% male and 35.59% female. Among them, 47.57% were etiologically positive and 16.35% had comorbidities. The overall successful treatment rate was 95.77%, with a cure rate of 42.54%. Nine factors were identified to influence treatment success, including a higher proportion of females (OR = 1.178), students versus farmers (OR = 1.960), and etiologically negative cases (OR = 1.831). Initial treatment showed better success rates than retreatment (OR = 3.046), and patients without comorbidities had higher success rates than those with comorbidities (OR = 1.303). Fixed-dose combination therapy (FDC) also yielded better outcomes (OR = 1.296). Ethnic differences were noted, with the Miao group having lower success rates (OR = 0.874) and the Buyi group higher success rates (OR = 1.270) compared to Han. Age was another factor, with success rates decreasing in the 41-60 (OR = 0.731) and 61 + age groups (OR = 0.604).
Conclusions: Western China faces ongoing challenges in enhancing its PTB treatment capacity and should prioritize the promotion of FDC therapy. Risk factors that influence treatment outcomes for PTB include male gender, advanced age, belonging to the Miao ethnic group, occupation as a farmer, etiological positivity, retreatment status, and comorbidities such as diabetes and HIV/AIDS. Further investigation is warranted to explore the disparities in successful treatment rates among different ethnicities.
Keywords: China’s Guizhou; Influencing factors; Multivariate regression analysis; Pulmonary tuberculosis; Successful treatment.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Conflict of interest: All the authors declared that there was no conflict of interest in the study.
Figures



Similar articles
-
Epidemiological characteristics, diagnosis and treatment effect of rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Guizhou Province.BMC Infect Dis. 2024 Sep 27;24(1):1058. doi: 10.1186/s12879-024-09976-9. BMC Infect Dis. 2024. PMID: 39333894 Free PMC article.
-
Prevalence trends, population characteristics and treatment outcomes of tuberculosis combined with diabetes in Southwest China: a register-based retrospective study.Front Public Health. 2024 Nov 20;12:1445857. doi: 10.3389/fpubh.2024.1445857. eCollection 2024. Front Public Health. 2024. PMID: 39635223 Free PMC article.
-
Tuberculosis disease burden in China: a spatio-temporal clustering and prediction study.Front Public Health. 2025 Jan 7;12:1436515. doi: 10.3389/fpubh.2024.1436515. eCollection 2024. Front Public Health. 2025. PMID: 39839385 Free PMC article.
-
Spatial epidemiological analysis based on township scale and analysis of influencing factors of pulmonary tuberculosis cure of Changshu city from 2015 to 2022.PLoS One. 2025 Jan 16;20(1):e0317269. doi: 10.1371/journal.pone.0317269. eCollection 2025. PLoS One. 2025. PMID: 39820225 Free PMC article.
-
Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.Infect Dis Poverty. 2020 May 7;9(1):50. doi: 10.1186/s40249-020-00660-z. Infect Dis Poverty. 2020. PMID: 32381098 Free PMC article. Clinical Trial.
References
-
- World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.
-
- Yang X. Analysis of National tuberculosis epidemic characteristics and multi-regional incidence prediction from 2004 to 2014. Lanzhou: Lanzhou University; 2017.
-
- Lu LP. Statistical analysis of the distribution characteristics of tuberculosis incidence in China. Lanzhou: Lanzhou University of Finance and Economics; 2019.
-
- Yang LJ. Study on Spatial distribution characteristics and influencing factors of tuberculosis. Beijing: Chinese Center for Disease Control and Prevention; 2020.
-
- Jiang H, Liu MY, Zhang YJ. Study on the Change regularity of Tuberculosis epidemic in China from 2005 to 2016// Compilation of papers of the 33rd National Academic Conference of China Tuberculosis Prevention Association and China Tuberculosis Science and Technology Award Presentation Conference. Qingdao: China National Tuberculosis Association, Chongqing Zhifei Biological Products Co., LTD., 2021:176–177.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources